Complete Genome of the Attenuated Sparfloxacin-Resistant Streptococcus agalactiae Strain 138spar

Julia W Pridgeon1, Dunhua Zhang2, Lee Zhang3

  • 1Aquatic Animal Health Research Unit, USDA, ARS, Auburn, Alabama, USA Julia.Pridgeon@ars.usda.gov.

Insights

Researchers developed an attenuated Streptococcus agalactiae strain, 138spar, by selecting for sparfloxacin resistance. Its complete genome sequence provides a resource for comparative genomics to understand virulence and antibiotic resistance.

Area of Science:

  • Microbiology
  • Genomics

Background:

  • Streptococcus agalactiae (Group B Streptococcus) is a significant human pathogen.
  • Understanding the genetic basis of bacterial attenuation is crucial for developing safer vaccines and therapeutics.

Purpose of the Study:

  • To generate a whole-genome sequence of an attenuated Streptococcus agalactiae strain.
  • To provide a genomic resource for identifying genes related to virulence and antibiotic resistance.

Main Methods:

  • Development of an attenuated strain (138spar) through selection for resistance to the antibiotic sparfloxacin.
  • Whole-genome sequencing of the attenuated S. agalactiae 138spar strain.

Main Results:

  • The complete genome size of S. agalactiae 138spar was determined to be 1,838,126 base pairs.
  • The genome sequence is now available for further analysis.

Conclusions:

  • The genome sequence of the attenuated S. agalactiae 138spar strain is a valuable resource.
  • Comparative genomic studies using this sequence can elucidate genes involved in virulence and antibiotic resistance in Streptococcus agalactiae.